Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06632379 · ClinicalTrials.gov registry record · Phase 4
AtorvaStatin Postpartum and Reduction of Cardiovascular risK
A Phase 4 study of Preeclampsia and Gestational Hypertension, sponsored by Ohio State University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT06632379: Recruiting Phase 4 study of Preeclampsia and Gestational Hypertension, sponsored by Ohio State University.
NCT06632379 is a Phase 4 study of Preeclampsia and Gestational Hypertension that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 76 participants, below the 1,125-participant average among 48 other Preeclampsia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06632379, a Phase 4 study of Preeclampsia and Gestational Hypertension, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.
Primary Outcome
Predicts 0-100% risk of "hard" CVD events (coronary death, myocardial infarction, stroke) based on sex, systolic blood pressure, antihypertensive treatment, total and high-density lipoprotein cholesterol, smoking, and diabetes mellitus. A higher number reflects a greater risk of adverse CVD events, whereas a lower number reflects lower risk.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atorvastatin 10 mg
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 4 |
What NCT06632379 shows while recruiting
NCT06632379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 1,125-participant average among 48 other Preeclampsia trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06632379 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06632379 about?
NCT06632379 is a clinical study titled "AtorvaStatin Postpartum and Reduction of Cardiovascular risK". The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be...
What is the current status of trial NCT06632379?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2025-10-03. Estimated completion is 2026-12-15.
What conditions does trial NCT06632379 study?
This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension, Hypertensive Disorders of Pregnancy.
What interventions are being tested in trial NCT06632379?
The interventions under investigation include: Placebo (DRUG), Atorvastatin 10 mg (DRUG).
Who is sponsoring clinical trial NCT06632379?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06632379 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06632379's enrollment target sits among peer trials
76 33rd of 48 higher than 16 of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
RECRUITING · Phase 4
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
RECRUITING · Phase 4
-
Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
ACTIVE NOT RECRUITING · Phase 4
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI